drugset / Trial / NCT05570058
Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
RandomizedSequentialTriple-blindTreatment
Summary
The purpose of the study is to assess the safety and tolerability of RXC007 when given for 12 weeks (84 days), alone and in combination with nintedanib or pirfenidone.
Timeline
- Start
- 2022-09-08
- Primary completion
- 2024-06-25
- Completion
- 2025-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RXC007 | Unknown | 20 mg | Oral |
| Subject | RXC007 | Unknown | 50 mg | Oral |
| Subject | RXC007 | Unknown | 70 mg | Oral |